title: Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia.
abstract: Approximately 40% of adults with chronic myeloid leukemia (CML) in prolonged complete molecular response (CMR) remain in CMR after imatinib discontinuation. Corresponding information in children is lacking. Two children with CML in CMR for 48 and 19 months after imatinib discontinuation showed low-level fluctuating disease at RNA transcript and genomic DNA levels. Both patients were low risk according to adult criteria. Since adults with molecular relapse responded to re-introduction of imatinib, we postulated that treatment discontinuation in low risk children might be justified within clinical trials with close monitoring. This may help to minimize exposure to imatinib and its potential side effects.
authors.affiliation: Department of Pediatric Hematology and Oncology, University Hospital Bonn, Bonn, Germany.
authors.forename: Olga
authors.initials: O
authors.lastname: Moser
authors.forename: Manuela
authors.initials: M
authors.lastname: Krumbholz
authors.forename: Christian
authors.initials: C
authors.lastname: Thiede
authors.forename: Josephine T
authors.initials: JT
authors.lastname: Tauer
authors.forename: Indra
authors.initials: I
authors.lastname: Janz
authors.forename: Melchior
authors.initials: M
authors.lastname: Lauten
authors.forename: Dagmar
authors.initials: D
authors.lastname: Dilloo
authors.forename: Markus
authors.initials: M
authors.lastname: Metzler
authors.forename: Meinolf
authors.initials: M
authors.lastname: Suttorp
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D002648:Child; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction
chemical_list: D000970:Antineoplastic Agents; C581634:BCR-ABL1 fusion protein, human; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl
keywords: CML; childhood; imatinib